Company profile

ZyVersa Therapeutics, Inc.

Pipeline2 assets

VAR 200Cholesterol Efflux Pathway (ABCA1 and ABCG1) / Cholesterol Efflux Mediator / Renal Diseases
Focal Segmental Glomerulosclerosis (FSGS)Phase 2activeUnited StatesDiabetic Kidney Disease (DKD)Phase 2activeUnited StatesAlport SyndromePreclinicalactiveUnited States
IC 100Inflammasome ASC / Monoclonal Antibody / Inflammatory Diseases
Cardiometabolic Conditions (Obesity-associated)PreclinicalactiveUnited StatesParkinson's DiseasePreclinicalactiveUnited StatesOrphan Renal DiseasesPreclinicalactiveUnited States

Latest news2 items

May 13, 2026

ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion. Inflammasome ASC Inhibitor IC 100 is the next evolution of inflammasome inhibitors designed for unparalleled control of disease-causing inflammation by (1)

Mar 31, 2026

ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update

ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion. Inflammasome ASC Inhibitor IC 100 is a next generation drug designed for unparalleled control of disease-causing inflammation by (1) inhibiting multiple